Search Results
Oct 23, 2025, 09:00 ET 62% of Organizations Cite Security and Privacy Risks as Top Concern with AI in DevOps
(54%) Overreliance on inexperienced developers (48%) Lack of integration with existing DevOps/CI/CD pipelines (45%) Limited control over generated architecture or design choices (44%) Unclear IP
More news about: Perforce Software
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
Notably, a US competitor focusing on CD47/SIRPα published findings in JHO in November 2020, reporting on a third-generation anti-CD47–SIRPα therapy. This underscores the journal's strong recognition within the field. The continued publication of anti-CD47 biologics in JHO highlights both the scientific
More news about: HanchorBio Inc.
Oct 22, 2025, 17:31 ET Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
clinical trial activities and the launch of emerging therapies such as lixudebart (Alentis Therapeutics), mezagitamab (Takeda Pharmaceutical), felzartamab (CD38) (Biogen), LNP023 (Novartis), NKX019 (Nkarta), and others will further propel the market.
More news about: DelveInsight Business Research, LLP
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
single-domain antibody library. It has advantages of high affinity, high specificity, and low immunogenicity. The intracellular domain is a fusion of 4-1BB (CD137) and CD3ζ signaling domains. RD118 has been subjected to extensive development and optimization in terms of antibody screening and structure design. The
More news about: IASO Bio
Oct 22, 2025, 03:45 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 22, 2025, 00:01 ET Silicon Labs Unveils the Next Evolution of IoT Development with the Simplicity Ecosystem
Commander – A command-line tool for programming, debugging, and security configuration. Engineers can erase, flash, or query devices, making it ideal for CI/CD and production automation.
More news about: Silicon Labs
Oct 21, 2025, 20:25 ET Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
and activates the IL-2 pathway. Innovent has shown that IBI363, with an IL-2 receptor alpha focused approach, selectively expands tumor-specific CD8+ T cells that increase tumor cell killing efficiency without activating or expanding the toxicity related to peripheral T cells, which results in
More news about: Innovent Biologics
Oct 21, 2025, 16:01 ET Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
IgG concentrations, robust CD4+ T-cell frequencies, and VRRs (per IgG and CD4+ criteria) comparable to Shingrix, at 4 weeks after dose 2 In new data presented at IDWeek, Z-1018 induced a high proportion of polyfunctional CD4+ T-cell responses exhibiting
More news about: Dynavax Technologies
Oct 21, 2025, 14:16 ET Jo - The Little Women Musical Announces World Premiere Semi-Staged West End Concert
winner Nigel Wright and Dan Redfeld. The album is available on all platforms including Spotify, iTunes, Apple Music and Amazon Music and as a special 2-CD set available on Center Stage Records. Dan Redfeld, Composer and Music Producer, said: "Following the amazing critical response
More news about: 4 Times Entertainment, Inc.
Oct 21, 2025, 08:05 ET The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
Medical Director, Oncology/Hematology, overseeing the expansion of the clinical development programs of both mosunetuzumab and glofitamab (CD20/CD3 bispecific antibodies). Dr. O'Hear earned her M.D. and Ph.D. from the University of Washington, followed by residency at Children's Hospital Boston,
More news about: Institute for Follicular Lymphoma Innovation (IFLI)
Oct 21, 2025, 07:00 ET HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
enhance the binding affinity and functional potency of HCB101 toward CD47 expressed on tumor cells, thereby reactivating macrophage-mediated cancer cell killing while minimizing the hematologic toxicities commonly associated with traditional CD47 monoclonal antibody therapies. The USPTO
More news about: HanchorBio Inc.
Oct 21, 2025, 07:00 ET VxLabs bringt ThreatZ auf den Markt, eine KI-gestützte Plattform für Cybersicherheit und Compliance im Automobilbereich für ISO/SAE 21434 und UNECE R155
über den gesamten Lebenszyklus hinweg kontinuierlich auditfähig hält. Es optimiert das dynamische Risikomanagement und die Validierung in CI/CD-Prozessen und passt sich an Live-Sicherheitsereignisse und neu auftretende Schwachstellen an, die in Flotten und Open-Source-Ökosystemen beobachtet werden.
More news about: VxLabs GmbH
Oct 21, 2025, 07:00 ET VxLabs Launches ThreatZ, an AI-Powered Automotive Cybersecurity & Compliance Platform for ISO/SAE 21434 and UNECE R155
platform that keeps organizations continuously audit-ready across the lifecycle. It streamlines dynamic risk management and validation into CI/CD processes and adapts to live security events and emerging vulnerabilities observed across fleets and open-source ecosystems. An AI knowledge graph
More news about: VxLabs GmbH
Oct 21, 2025, 07:00 ET VxLabs Launches ThreatZ, an AI-Powered Automotive Cybersecurity & Compliance Platform for ISO/SAE 21434 and UNECE R155
platform that keeps organizations continuously audit-ready across the lifecycle. It streamlines dynamic risk management and validation into CI/CD processes and adapts to live security events and emerging vulnerabilities observed across fleets and open-source ecosystems. An AI knowledge graph
More news about: VxLabs GmbH
Oct 21, 2025, 06:00 ET PEOPLES BANCORP INC. ANNOUNCES THIRD QUARTER 2025 RESULTS
Return on average tangible equity (c)(d)
More news about: Peoples Bancorp Inc.
Oct 20, 2025, 19:39 ET BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Oct 20, 2025, 16:10 ET MATSON TO ANNOUNCE THIRD QUARTER 2025 RESULTS ON NOVEMBER 4, 2025
https://register-conf.media-server.com/register/BI5943b35b1672471286990cd51612a1b2 Registered participants will receive the conference
More news about: Matson, Inc.
Oct 20, 2025, 10:04 ET FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis
developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease. Gazyva is a type II humanized anti-CD20 monoclonal antibody that works by targeting and eliminating certain B cells, which are believed to promote inflammation which causes kidney damage
More news about: Lupus Foundation of America, Inc.
Oct 20, 2025, 09:00 ET Mountain Commerce Bancorp, Inc. Announces Third Quarter 2025 Results and Quarterly Cash Dividend
Brokered CD
More news about: Mountain Commerce Bancorp, Inc.
Oct 20, 2025, 08:40 ET Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis
Northwell, the study's lead investigator, and a member of LuCIN. "Obinutuzumab, the first anti-CD20 therapy currently approved for lupus nephritis, enhances B-cell depletion compared to previously studied anti-CD20 antibodies, providing complete renal response in nearly half of patients studied, without
More news about: Lupus Research Alliance
Oct 20, 2025, 08:30 ET AbelZeta Announces Late-Breaking Poster Presentation at ACR Convergence 2025 of First-in-Human Phase I Trial of anti-CD20/BCMA Bispecific CAR-T Therapy in Patients with Refractory Autoimmune Diseases
College of Rheumatology (ACR) Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois. C-CAR168 is an autologous anti-CD20/BCMA bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to simultaneously target autoantibody-producing plasma cells and their B-cell
More news about: AbelZeta Pharma, Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
healthcare provider does not recommend TNF blockers. Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection
More news about: AbbVie
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
About HCB101: A Differentiated CD47-SIRPα BlockadeHCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio's proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood
More news about: HanchorBio Inc.
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). Antengene has also developed
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and CD8+ T cells, collectively demonstrating effective PD-1 and CTLA-4 inhibition.Serum-free VEGFA reduced deeply and rapidly across all dose levels,
More news about: CStone Pharmaceuticals